Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma

Published:2007-09 Issue:6 Volume:5 Page:379-385
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Cho Daniel,Signoretti Sabina,Dabora Sandra,Regan Meredith,Seeley Apryle,Mariotti Mauro,Youmans Amanda,Polivy Adam,Mandato Lucy,McDermott David,Stanbridge Eric,Atkins Michael

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference21 articles.

1. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC);Hudes;J Clin Oncol,2006

2. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy;Hidalgo;Oncogene,2000

3. Loss of tumor suppressor protein PTEN during renal carcinogenesis;Brenner;Int J Cancer,2002

4. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis;Velickovic;Mod Pathol,2002

5. Using tumor markers to predict survival of patients with metastatic renal cell carcinoma;Kim;J Urol,2005

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis;Journal of Personalized Medicine;2024-05-23

2. The emerging genetic landscape of renal cell carcinoma;Diagnostic Molecular Pathology;2024

3. Contemporary Clinical Definitions, Differential Diagnosis, and Novel Predictive Tools for Renal Cell Carcinoma;Biomedicines;2022-11-14

4. The Ambivalent Role of miRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications;Pharmaceuticals;2021-04-02

5. Mechanisms of resistance to mTOR inhibitors;Critical Reviews in Oncology/Hematology;2020-03